As per the Retail Audit Data of FPP in the Russian Federation form January-September 2018, the volume of the Russian pharmacy market grew by 6% in Ruble terms and by 1% in dollars and reached to 660.183 billion rubles. In physical terms, the volume of sales of drugs declined relative to the same period of 2017 by 1% and was equal to 3.244 billion rubles. A slight decrease observed in the average expenses of Russians for the purchase of medicines, and the average cost of packaging increased from the last year.

The top ten companies accumulated 34.2% of the Russian market in the first nine months of 2018. The top three international nonproprietary names (INNs) and group names Ibuprofen, combination Diosmin and Hesperidin, and Xylometazoline have not changed. Bisoprolol shifted up to the fourth rank, whereas the earlier less dynamic Pancreatin migrated down to rank five, Rivaroxaban and Ethylmethylhydroxypyridine to eighth and ninth, respectively. The total share of the top ten, raised from 9.6% to 9.8%.

Also, some of the leading ATC groups rating in the country's market remained unchanged. The group M01 anti-inflammatory and antirheumatic products and C09 Preparations influencing the renin-angiotensin system continue to occupy first two positions. B1 Anticoagulants shifted up to rank five from ninth, and G03 Sex hormones shifted from four to three rank. The last line of the rating was grasped for the first time by C05 Angioprotectors. Concurrently, five groups (J01 Antibacterial preparations for systemic use, R01 Nasal preparations, J05 Antivirals for systemic use, N02 Analgesics, and A07 Antidiarrheal, intestinal anti-inflammatory and antimicrobial drugs) dropped by one rating position. On the whole, the share of the top ten ATC groups estimated for 36.3%. These findings are of the first nine months of 2018.